| Literature DB >> 34259640 |
Tyler Shelby1,2, Xin Zhou3, Douglas Barber1, Frederick Altice2,3,4.
Abstract
BACKGROUND: Harm reduction services reduce the negative consequences of drug injection and are often embedded within syringe service programs (SSPs). However, people who inject drugs (PWID) suboptimally engage with such services because of stigma, fear, transportation restrictions, and limited hours of operation. Mobile health (mHealth) apps may provide an opportunity to overcome these barriers and extend the reach of SSPs beyond that of the traditional brick-and-mortar models.Entities:
Keywords: mHealth; mobile phone; patient preferences; people who inject drugs; service access; syringe services programs
Mesh:
Substances:
Year: 2021 PMID: 34259640 PMCID: PMC8319773 DOI: 10.2196/25428
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Frequencies and percentages of Likert responses for component interests and comfort engaging with home syringe delivery (n=110).
| Interestsa | Extremely useful, n (%) | Very useful, n (%) | Moderately useful, n (%) | Slightly useful, n (%) | Not at all useful, n (%) |
| Delivery of PrEPb services (n=108) | 26 (24.1) | 32 (29.6) | 35 (32.4) | 5 (4.6) | 10 (9.3) |
| Delivery of syringes | 47 (42.7) | 45 (40.9) | 13 (11.8) | 1 (0.9) | 4 (3.6) |
| Delivery of medications for opioid use disorder | 57 (51.8) | 32 (29.1) | 11 (10) | 1 (0.9) | 9 (8.2) |
| Linking to electronic medical record to schedule appointments with clinical provider | 43 (39.1) | 41 (37.3) | 20 (18.2) | 5 (4.6) | 1 (0.9) |
| Being scheduled for laboratory testing (eg, HIV, hepatitis C virus, and sexually transmitted infections; n=109) | 44 (40.4) | 41 (37.6) | 17 (15.6) | 5 (4.6) | 2 (1.8) |
| Reminders to take medication | 43 (39.1) | 34 (30.9) | 17 (15.5) | 11 (10) | 5 (4.6) |
| Receive educational materials | 33 (30) | 32 (29.1) | 29 (26.4) | 7 (6.4) | 9 (8.2) |
| Group communication forums | 34 (30.9) | 30 (27.3) | 29 (26.4) | 8 (7.27) | 9 (8.2) |
| Comfort with home syringe deliveryc (n=109) | 45 (41.3) | 48 (44) | 2 (1.8) | 8 (7.3) | 6 (5.5) |
aUnless specified as comfort rather than interest.
bPrEP: pre-exposure prophylaxis.
cThis Likert scale included very comfortable, comfortable, unsure, uncomfortable, and very uncomfortable.
Characteristics and survey responses of study participants (N=115).
| Participant characteristics | Values | ||||
|
| |||||
|
|
| ||||
|
|
| Value, mean (SD) | 41.7 (10.6) | ||
|
|
|
| |||
|
|
|
| 18-34 | 37 (32.2) | |
|
|
|
| 35-49 | 48 (41.7) | |
|
|
|
| ≥50 | 30 (26.1) | |
|
|
| ||||
|
|
| Male | 78 (67.8) | ||
|
| Hispanic ethnicity, n (%) | 27 (23.5) | |||
|
|
| ||||
|
|
| White | 74 (70.5) | ||
|
|
| Black or African American | 17 (16.2) | ||
|
|
| Other | 14 (13.3) | ||
|
| Financial stability score, median (Q1, Q3) | 3 (1, 5) | |||
|
| Completed high school, n (%) | 87 (75.7) | |||
|
| Currently homeless or unstably housed, n (%) | 72 (62.6) | |||
|
| Ever incarcerated, n (%) | 96 (83.5) | |||
|
| |||||
|
| Years of injecting, mean (SD) | 14 (11.9) | |||
|
| Self-reported HIV positivity (n=110), n (%) | 9 (8.2) | |||
|
| Self-reported hepatitis C virus positivity, n (%) | 35 (30.4) | |||
|
| Syringe sharing with current injection partners, n (%) | 101 (87.8) | |||
|
| Carry Narcan while injecting, n (%) | 49 (42.6) | |||
|
| Recent syringe service program use, n (%) | 64 (55.7) | |||
|
| Overdose, ever, n (%) | 70 (60.9) | |||
|
| |||||
|
|
| ||||
|
|
| Cellphone without internet | 12 (11) | ||
|
|
| Smartphone | 74 (67.9) | ||
|
|
| Tablet | 2 (1.8) | ||
|
|
| Computer | 6 (5.5) | ||
|
|
| None | 22 (20) | ||
|
|
| ||||
|
|
| Name | 96 (88.1) | ||
|
|
| Personal phone number | 92 (84.4) | ||
|
|
| Personal email | 85 (78) | ||
|
|
| Home address | 85 (78) | ||
|
|
| Alternative address | 62 (56.9) | ||
|
|
| Medical records | 72 (66.1) | ||
|
| Comfort with home delivery of syringesa | 93 (85.3) | |||
|
|
| ||||
|
|
| Delivery (PrEPb, syringes, and medications for opioid use disorder) | 100 (90.9) | ||
|
|
| Clinical scheduling (provider and lab) | 90 (81.8) | ||
|
|
| Medication reminders | 77 (70) | ||
|
|
| Health education | 65 (59.1) | ||
|
|
| Group communication forums | 64 (58.2) | ||
|
| |||||
|
| Access to smartphone, n (%) | 74 (67.9) | |||
|
| Comfort (0-7), mean (SD) | 5.4 (1.8) | |||
|
| Interest (0-5; n=110), mean (SD) | 3.6 (1.5) | |||
aSee Table 1 for full Likert score responses. The proportion of participants who perceived home delivery of syringes as comfortable or very comfortable and the proportion of those who perceived services as very or extremely useful are shown here.
bPrEP: pre-exposure prophylaxis.
Multivariable logistic and Poisson models for primary outcomesa,b.
| Covariates | Primary Outcomes | ||||||||||||||
|
| Access to smartphone | Comfort providing personal identifiers and engaging with personalized services | Interest in comprehensive mobile health services | ||||||||||||
|
| AORc (95% CI) | Coefficient (95% CI) | Coefficient (95% CI) | ||||||||||||
|
| |||||||||||||||
|
| 18-34 | Refd | Ref | —e | — | Ref | Ref | ||||||||
|
| 35-49 | 2.78 (0.99 to 7.82) | .05 | — | — | 0.05 (−0.19 to 0.30) | .68 | ||||||||
|
| ≥50 | 1.04 (0.32 to 3.43) | .95 | — | — | 0.21 (−0.07 to 0.48) | .14 | ||||||||
| Financial stability >3 | 1.74 (0.66 to 4.59) | .27 | — | — | — | — | |||||||||
| Completed high school | — | — | 0.13 (−0.07 to 0.33) | .19 | — | — | |||||||||
|
|
|
| — | — | — | — | |||||||||
| HIV positivity | — | — | — | — | 0.15 (−0.21 to 0.51) | .42 | |||||||||
aLogistic regression used for access primary outcome.
bPoisson regression used for comfort and interest primary outcomes.
cAOR: adjusted odds ratio.
dRef: reference group.
eNot available. The covariate was not included in the final model because it did not meet the bivariate threshold of P<.20.
fItalicized text denotes significance (P<.05).
Secondary multivariable logistic regression models evaluating individual comfort items.
| Covariates | Individual comfort items | ||||||||||||||||
|
| Name | Phone number | Address | Medical records | Home syringe delivery | ||||||||||||
|
| AORa | AOR | AOR | AOR | AOR | AOR | |||||||||||
|
| |||||||||||||||||
|
| 18-34 | Refb | Ref | Ref | Ref | —c | — | Ref | Ref | — | — | — | — | ||||
|
|
| 0.51 (0.09-2.92) | .45 |
|
| — | — | 2.26 (0.75-6.78) | .15 | — | — | — | — | ||||
|
| ≥50 | 0.49 (0.05-5.23) | .56 | 0.77 (0.25-2.39) | .65 | — | — | 1.22 (0.39-3.81) | .74 | — | — | — | — | ||||
| Female | — | — | — | — | — | — | 2.05 (0.69-6.13) | .20 | — | — | — | — | |||||
| Hispanic ethnicity | — | — | 0.36 (0.11-1.12) | .08 | — | — | — | — | — | — | — | — | |||||
|
| 1.74 (0.48-6.26) | .40 | — | — | — | — | — | — |
|
| — | — | |||||
| Homeless or unstably housed | 0.20 (0.39-1.00) | .05 | — | — | — | — | — | — | 0.52 (0.22-1.27) | .15 | — | — | |||||
| Ever been incarcerated | — | — | 2.50 (0.78-8.10) | .13 | — | — | — | — | — | — | — | — | |||||
| Years of injecting | 0.96 (0.90-1.03) | .29 | — | — | — | — | — | — | 0.98 (0.95-1.02) | .37 | — | — | |||||
|
| — | — | — | — | 1.79 (0.61-5.24) | .29 | — | — | — | — |
|
| |||||
| Carry Narcan | — | — | — | — | 1.96 (0.62-6.15) | .25 | — | — | — | — | — | — | |||||
| Syringe sharing | — | — | — | — | — | — | — | — | 2.21 (0.67-7.26) | .19 | 2.69 (0.70-10.37) | .15 | |||||
aAOR: adjusted odds ratio.
bRef: reference group.
cNot available. The covariate was not included in the final model because it did not meet the bivariate threshold of P<.20.
dItalicized text denotes significance (P<.05).
eSSP: syringe service program.
Secondary multivariable logistic regression models evaluating individual interest items.
| Covariates | Individual interest items | ||||||||||||||||||||
|
| Delivery | Scheduling | Reminders | Educational material | Communication forums | ||||||||||||||||
|
| AORa | AOR | AOR | AOR | AOR | ||||||||||||||||
|
| |||||||||||||||||||||
|
| 18-34 | —b | — | — | — | Refc | Ref | Ref | Ref | Ref | Ref | ||||||||||
|
| 35-49 | — | — | — | — | 1.79 (0.65-4.91) | .26 | 0.97 (0.36-2.59) | .95 | 1.23 (0.46-3.29) | .68 | ||||||||||
|
| ≥ | — | — | — | — | 5.05 (0.95-26.72) | .06 |
|
|
|
| ||||||||||
|
| |||||||||||||||||||||
|
| White | Ref | Ref | — | — | Ref | Ref | — | — | Ref | Ref | ||||||||||
|
| Black or African American | 0.37 (0.07-1.96) | .24 | — | — | 1.59 (0.38-6.65) | .52 | — | — | 1.31 (0.37-4.63) | .67 | ||||||||||
|
| Other | 0.28 (0.04-1.91) | .20 | — | — | 1.15 (0.34-3.97) | .82 | — | — | 1.13 (0.32-4.02) | .85 | ||||||||||
| Female | 2.90 (0.32-26.86) | .35 | — | — | — | — | — | — | — | — | |||||||||||
| Hispanic ethnicity | — | — | 0.44 (0.14-1.33) | .15 | — | — | 2.17 (0.69-6.75) | .18 | 2.01 (0.57-7.02) | .28 | |||||||||||
| Completed high school | — | — | 1.88 (0.62-5.70) | .27 | — | — | — | — | — | — | |||||||||||
|
| — | — | — | — | — | — |
|
| — | — | |||||||||||
| HIV positivity | — | — | — | — | — | — | 3.52 (0.36-34.62) | .28 | — | — | |||||||||||
| HCVepositivity | — | — | — | — | — | — | — | — | 0.46 (0.19-1.14) | .09 | |||||||||||
| Years of injecting | 0.97 (0.92-1.03) | .34 | — | — | 1.00 (0.95-1.05) | .99 | — | — | — | — | |||||||||||
| Carry Narcan | 3.29 (0.61-17.73) | .17 | — | — | — | — | 0.57 (0.24-1.38) | .21 | — | — | |||||||||||
aAOR: adjusted odds ratio.
bNot available. The covariate was not included in the final model because it did not meet the bivariate threshold of P<.20.
cRef: reference group.
dItalicized text denotes significance (P<.05).
eHCV: hepatitis C virus.